急性髓系白血病干细胞的研究现状和进展

Research status and progress of acute myeloid leukemia stem cells

急性髓系白血病(AML)是造血系统的髓系原始细胞克隆性恶性增殖性疾病。白血病细胞群由不同阶段的细胞组成,在免疫缺陷的动物体内可能引起疾病并可通过引起白血病的持续移植自我再生的细胞是AML干细胞(AML-LSCs)。由于超过96%的LSCs处于G0阶段,它们可能逃脱化学药物的影响,导致药物耐药性和白血病复发。因此,治疗AML的关键一直是如何在不损害造血干细胞(HSCs)的情况下去除LSCs。本文将重点介绍LSCs的免疫表型和靶向治疗方面的新进展。

Acute myeloid leukemia is a clonal malignant proliferative disease of myeloid blasts of the hematopoietic system.The leukemia cell population is composed of cells of different stages.Acute myeloid leukemia stem cells are the cells that may cause diseases in immunodeficient animals and can regenerate themselves through continuous transplantation,which causes leukemia.Since more than 96%of leukemia stem cells are in the G0 stage,they may escape the effects of chemical drug stabbing,leading to drug resistance and recurrence of leukemia.Therefore,the key to the treatment of acute myeloid leukemia has always been how to remove leukemia stem cells without damaging hematopoietic stem cells.This review paper addresses the new developments in the immunophenotype of leukemia stem cells and leukemia stem cells-targeting therapy for acute myeloid leukemia.